Mei Cai joins Charming Medical (NASDAQ: MCTA) as independent audit chair
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Charming Medical Limited reported board changes, with independent director Matthew Mo Kan Tsui resigning effective April 27, 2026, to pursue other business commitments, with no disagreement on operations, policies, or procedures.
On May 2, 2026, the board appointed Mei CaiUS$50,000. The board determined she is an independent director under U.S. SEC and Nasdaq rules and qualifies as an audit committee financial expert. Ms. Cai was named chairman of the Audit Committee and a member of the Compensation and Nominating Committees.
Positive
- None.
Negative
- None.
Key Figures
Director annual compensation: US$50,000
Mei Cai age: 47
Experience duration: Over 20 years
+3 more
6 metrics
Director annual compensation
US$50,000
Annual pay for Mei Cai as director, effective May 2, 2026
Mei Cai age
47
Age disclosed in biographical information
Experience duration
Over 20 years
Accounting, auditing, SEC reporting, corporate finance, U.S. capital markets
Nuance Biotech CFO tenure
January 2023 to October 2023
CFO of Nuance Biotech Co., Ltd.
Jowell Global CFO tenure
November 2020 to December 2022
CFO of Jowell Global Ltd. (Nasdaq: JWEL)
China Eco-Materials CFO tenure
July 2019 to November 2020
CFO of China Eco-Materials Group Co., Ltd.
Key Terms
independent director, audit committee financial expert, Nasdaq Marketplace Rules, Regulation S-K, +1 more
5 terms
independent director financial
"Mr. Matthew Mo Kan Tsui notified the Company of his resignation as an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
audit committee financial expert financial
"qualifies as an “audit committee financial expert” as defined under Item 407(d)(5) of Regulation S-K"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
Nasdaq Marketplace Rules regulatory
"is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules"
A set of standards and procedures that govern how stocks and other securities are listed, traded and monitored on the Nasdaq exchange; think of it as the marketplace rulebook that sets eligibility, disclosure, trading conduct and enforcement practices. Investors care because these rules affect whether a company can be listed or removed, how transparently it must report information, and how fairly trades are executed — all of which influence risk and the ability to buy or sell shares.
Regulation S-K regulatory
"as defined under Item 407(d)(5) of Regulation S-K promulgated under the Securities Exchange Act of 1934"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
FAQ
Why did Matthew Mo Kan Tsui resign from Charming Medical (MCTA)?
Mr. Matthew Mo Kan Tsui resigned as an independent director on April 27, 2026 to pursue other business commitments. The company states his resignation was not due to any disagreement with its operations, policies, or procedures, indicating a routine change rather than a governance dispute.
Who is Mei Cai, the new director of Charming Medical (MCTA)?
Mei Cai is a 47-year-old finance professional with over 20 years of experience in accounting, auditing, SEC reporting, corporate finance, and U.S. capital markets. She previously served as CFO at several companies and has held director roles at Nasdaq-listed firms, plus consulting and audit positions.
What role will Mei Cai have on Charming Medical’s (MCTA) board?
Mei Cai will serve as a non-employee, independent director on the board. She has been appointed chairman of the Audit Committee and a member of both the Compensation Committee and Nominating Committee, giving her key oversight responsibilities in financial reporting, executive pay, and board nominations.
How much will Charming Medical (MCTA) pay Mei Cai as director compensation?
The company approved annual compensation of US$50,000 for Mei Cai’s service as a director. This pay reflects her responsibilities as an independent director, chairman of the Audit Committee, and member of the Compensation and Nominating Committees, as specified in her director offer letter dated May 2, 2026.
Is Mei Cai considered an independent director at Charming Medical (MCTA)?
Yes, the board determined that Mei Cai qualifies as an independent director under applicable U.S. SEC and Nasdaq Marketplace Rules. She is also described as a non-employee director, with no family relationships with company employees or other board members disclosed in the report.
Does Mei Cai qualify as an audit committee financial expert at Charming Medical (MCTA)?
The board determined that Mei Cai qualifies as an audit committee financial expert under Item 407(d)(5) of Regulation S-K. They also state she possesses the required financial sophistication under Nasdaq Listing Rule 5605(c)(2)(A), supporting her appointment as chairman of the Audit Committee.